Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The research service ...

Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

Eli Lilly (LLY) ended the recent trading session at $762.18, demonstrating a -1.23% change from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily gain of 0.14% ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Eli Lilly stock is a no-brainer buy right now. For Eli Lilly to reach a $1 trillion market cap within the next couple of years, it would need to rise by more than 50% from where it is today.

Today, Eli Lilly trades at a multiple of 10 times revenue. Assuming that multiple remains intact, then Eli Lilly's revenue would need to be at around $100 billion for the stock to be worth $1 ...

Summary. Eli Lilly's share price performance over the past 5 years is +290%. The rest of the US Big Pharma sector averages a gain of ~30%. Lilly's valuation seems impossibly high, based on $28.bn ...

Eli Lilly continued to grow like a weed in the second quarter. The company’s dividend payout ratio is somewhat low. Depending on your confidence in the future, the stock’s valuation may be ...

How Does Eli Lilly’s Valuation Look vs. The S&P 500? Going by what you pay per dollar of sales or profit, LLY stock looks very expensive compared to the broader market.

From a valuation perspective, LLY stock looks appropriately priced, but the massive demand for Zepbound and Mounjaro may continue to bolster its stock. Looking at Q2, Eli Lilly’s revenue of $11. ...

Eli Lilly is the most likely healthcare stock to reach a $1 trillion valuation, and I believe it could hit that plateau by 2027. Eli Lilly's stock has surged close to 400% in five years.